Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to an Approved JAK Inhibitors (HEMA-MED)

NCT06887803 is registered in ClinicalTrials.gov with iOnctura as lead sponsor.

NCT NCT06887803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06887803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label, Multi-centre Study to Assess the Safety and Tolerability of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to an Approved JAK Inhibitors (HEMA-MED)
Lead sponsor
iOnctura
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 17, 2025
Completion date
July 31, 2028
Enrollment
26 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis (mf)